StratifAI, a pioneering provider of AI-powered digital oncology solutions, today announced it has raised €1.5 million in pre-seed funding. The round was co-led by Neulogy Ventures and MultiplexDX, with participation from Debiopharm Innovation Fund, Arve Capital, as well as angel investor Christoph Haarburger.
This pre-seed funding will be instrumental in furthering the development of StratifAI’s cutting-edge technology, expanding its team of experts, and accelerating the market readiness of its digital oncology platform. The investment underscores the potential of StratifAI’s AI-driven approach to revolutionize cancer prognostication.
“We are thrilled to have the support of such a diverse and experienced group of investors in the pharmaceutical, biotech and precision oncology space”, said Omar El Nahhas, CEO and co-founder of StratifAI.
“This funding is a pivotal step in our mission to develop the next generation of AI-based biomarkers which improve cancer patient outcomes. With our investors’ backing, we’re well-positioned to bring our innovative solutions to oncologists and patients alike.”
Founded in 2023, StratifAI is at the forefront of digital innovation in the field of precision oncology. The company’s mission is to harness the power of AI to transform cancer prognosis, delivering accurate, actionable insights to oncologists that improve patient outcomes.
As cancer rates continue to rise globally, and treatment options become increasingly complex, there’s an urgent need for more efficient and accurate prognostic tools. StratifAI’s technology addresses this challenge by providing oncologists with AI-assisted analysis of tissue samples which brings an additional dimension of spatial biology that is otherwise lost.
With this pre-seed funding, StratifAI plans to finalize its product development, initiate pilot studies with key partners, and prepare for market entry through CE-IVDR certification. The company aims to establish itself as a leader in AI-powered digital oncology solutions.
This investment marks a significant milestone for StratifAI and reflects growing confidence in the potential of AI to transform healthcare. As the company progresses from pre-seed stage to product launch, it remains committed to its goal of improving cancer prognosis and, ultimately, patient outcomes.
